Skip to main content

Pharvaris N.V.

corporate_fare Company Profile

Pharvaris N.V.

PHVS·NASDAQ·Life Sciences·CIK 0001830487

Pharvaris N.V. is a late-stage biopharmaceutical company that develops and commercializes therapies for rare diseases with unmet needs, specifically focusing on angioedema and other diseases mediated by bradykinin. The company's primary product is deucrictibant, a small molecule bradykinin B2-receptor antagonist. Deucrictibant is being developed to treat attacks caused by bradykinin-mediated angioedema, including hereditary angioedema (HAE) and acquired angioedema due to C1-inhibitor deficiency (AAE-C1INH). This therapy is currently in Phase 3 trials for the treatment of HAE attacks and also in Phase 3 trials for the prophylaxis (prevention) of HAE attacks. Pharvaris N.V. is developing both an extended-release tablet and an immediate-release capsule formulation of deucrictibant. The company was incorporated in 2015 and its headquarters are located in Zug, Switzerland.

Pharvaris N.V. (NASDAQ:PHVS) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 22 items for PHVS at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-12, rated 7/10. Across its 20 most recent items scored 7 or higher, the top rating is 9/10, with 15 rated 8 or above. Recent SEC coverage for PHVS spans 6-K, 144, 424B5, 20-F.

Recent high-impact activity:

  • Pharvaris Q3 2026: €283M Cash, Loss Widens to €47.4M Ahead of April 2027 PDUFA
  • Pharvaris' Deucrictibant Phase 3 Data Published in The Lancet, Showing Rapid HAE Attack Resolution
  • Pharvaris Officer/Director Schikan Files to Sell 200,000 Shares Worth $7M
  • Pharvaris Insider Schoodic Management BV Files to Sell 300,000 Shares Worth $10.5M
  • Pharvaris CHAPTER-3 Data: 83% Attack Reduction, All Secondary Endpoints Met

Financial Snapshot

Fiscal year ended December 31, 2025
Net Income
-$175.7M
Diluted EPS
-$2.97
Op. Cash Flow
-$137.07M
Free Cash Flow
-$137.24M
Operating Income
-$173.71M
Cash & Equivalents
$291.68M
Debt / Equity
0.00×
Shares Outstanding
65.21M sh
Source: 20-F · filed 2026-04-02 · accession 0001830487-26-000013

Short Interest & Short Volume

3.58 days to cover

FINRA reported short interest of 2,539,475 shares in PHVS as of the October 30, 2026 settlement, a 3.0% increase from the prior period — about 3.6 days to cover at its recent average daily volume. On November 20, 2026, 36.5% of PHVS volume reported to FINRA trade-reporting facilities was marked short.

Short interest (bi-monthly positions)2,539,475 shares as of October 30, 2026
Change vs prior period▲ 3.0%
Days to cover3.58 at avg daily volume of 708,619
Daily short volume (FINRA facilities)36.5% of 246,717 shares on November 20, 2026
5-day average short volume44.6%

Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.

Insider Transactions

PHVS files as a Foreign Private Issuer (FPI). Under SEC Exchange Act Section 16(a), officers, directors, and 10% owners of FPIs are exempt from Form 4 insider-transaction reporting requirements. Comparable disclosures, when applicable, appear in the company's Form 20-F (annual) or Form 6-K (interim) filings on SEC EDGAR.

Browse all tickers starting with P →
$31.28
52-week range · as of 2026-11-12 $22.41 – $43.25
Market cap
$2.21B
Volume
464K (0.8× avg)
3-mo avg 572K
Live data · 2026-11-21 04:34 UTC · Market overnight

show_chartPrice Chart

Loading chart...

feed PHVS - Latest Insights

PHVS
Nov 12, 2026, 6:51 AM EST
Filing Type: 6-K
Importance Score:
7
Price at Filing: $34.18
Real-time Price: $31.28 info
Change: -$2.90 (-8%) info
Market Cap: $2.214B info
PHVS
Oct 08, 2026, 6:35 PM EDT
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $30.68
Real-time Price: $31.28 info
Change: +$0.600 (+2%) info
Market Cap: $2.214B info
PHVS
Sep 17, 2026, 5:27 PM EDT
Filing Type: 144
Importance Score:
7
Price at Filing: $37.96
Real-time Price: $31.28 info
Change: -$6.68 (-18%) info
Market Cap: $2.214B info
PHVS
Sep 17, 2026, 5:27 PM EDT
Filing Type: 144
Importance Score:
7
Price at Filing: $37.96
Real-time Price: $31.28 info
Change: -$6.68 (-18%) info
Market Cap: $2.214B info
PHVS
Sep 08, 2026, 9:00 AM EDT
Filing Type: 6-K
Importance Score:
9
Price at Filing: $42.40
Real-time Price: $31.28 info
Change: -$11.12 (-26%) info
Market Cap: $2.214B info
PHVS
Sep 08, 2026, 6:51 AM EDT
Filing Type: 6-K
Importance Score:
9
Price at Filing: $38.90
Real-time Price: $31.28 info
Change: -$7.62 (-20%) info
Market Cap: $2.214B info
PHVS
Sep 08, 2026, 6:50 AM EDT
Source: GlobeNewswire
Importance Score:
9
Price at Filing: $40.00
Real-time Price: $31.28 info
Change: -$8.72 (-22%) info
Market Cap: $2.214B info
PHVS
Aug 12, 2026, 6:51 AM EDT
Filing Type: 6-K
Importance Score:
8
Price at Filing: $33.05
Real-time Price: $31.28 info
Change: -$1.77 (-5%) info
Market Cap: $2.214B info
PHVS
Aug 12, 2026, 6:50 AM EDT
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $33.01
Real-time Price: $31.28 info
Change: -$1.73 (-5%) info
Market Cap: $2.214B info
PHVS
Jul 06, 2026, 6:50 AM EDT
Source: GlobeNewswire
Importance Score:
9
Price at Filing: $34.42
Real-time Price: $31.28 info
Change: -$3.14 (-9%) info
Market Cap: $2.214B info
PHVS
Jun 11, 2026, 6:52 AM EDT
Filing Type: 6-K
Importance Score:
8
Price at Filing: $32.13
Real-time Price: $31.28 info
Change: -$0.850 (-3%) info
Market Cap: $2.214B info
PHVS
May 12, 2026, 4:21 PM EDT
Source: Dow Jones Newswires
Importance Score:
7
Price at Filing: $31.25
Real-time Price: $31.28 info
Change: +$0.030 (+0.10%) info
Market Cap: $2.214B info
PHVS
May 12, 2026, 4:05 PM EDT
Filing Type: 6-K
Importance Score:
8
Price at Filing: $32.00
Real-time Price: $31.28 info
Change: -$0.720 (-2%) info
Market Cap: $2.214B info
PHVS
May 11, 2026, 4:41 PM EDT
Filing Type: 6-K
Importance Score:
8
Price at Filing: $30.00
Real-time Price: $31.28 info
Change: +$1.28 (+4%) info
Market Cap: $2.214B info
PHVS
May 11, 2026, 4:15 PM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $30.00
Real-time Price: $31.28 info
Change: +$1.28 (+4%) info
Market Cap: $2.214B info
PHVS
May 08, 2026, 5:13 PM EDT
Filing Type: 424B5
Importance Score:
8
Price at Filing: $30.09
Real-time Price: $31.28 info
Change: +$1.19 (+4%) info
Market Cap: $2.214B info
PHVS
May 08, 2026, 6:00 AM EDT
Source: Dow Jones Newswires
Importance Score:
8
Price at Filing: $29.20
Real-time Price: $31.28 info
Change: +$2.08 (+7%) info
Market Cap: $2.214B info
PHVS
Apr 02, 2026, 6:52 AM EDT
Source: Dow Jones Newswires
Importance Score:
8
Price at Filing: $27.60
Real-time Price: $31.28 info
Change: +$3.68 (+13%) info
Market Cap: $2.214B info
PHVS
Apr 02, 2026, 6:51 AM EDT
Filing Type: 20-F
Importance Score:
8
Price at Filing: $27.37
Real-time Price: $31.28 info
Change: +$3.91 (+14%) info
Market Cap: $2.214B info
PHVS
Apr 02, 2026, 6:50 AM EDT
Filing Type: 6-K
Importance Score:
8
Price at Filing: $27.37
Real-time Price: $31.28 info
Change: +$3.91 (+14%) info
Market Cap: $2.214B info
Research tools: Filing Impact Index Dilution Tracker Split Calendar Open Datasets